Last updated on February 2018

SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease


Brief description of study

To investigate the efficacy of the administration of JVS-100 delivered via direct intramuscular injections on a 3 month and 6 month composite endpoint of wound progression, healing and limb loss in patients with severe peripheral arterial disease with non-healing chronic wounds who undergo an open bypass grafting or endovascular procedure for treatment of infrapopliteal disease and are dosed within 12 days and 3 months following the procedure.

Clinical Study Identifier: NCT02544204

Find a site near you

Start Over

UC Davis

Davis, CA United States
  Connect »

Cedars-Sinai Heart Institute

Los Angeles, CA United States
  Connect »

MedStar Georgetown UH

Washington, WA United States
  Connect »

Morton Plant Hosptial - Baycare

Clearwater, FL United States
  Connect »

St. Joseph's Hospital

Tampa, FL United States
  Connect »

Northwestern

Chicago, IL United States
  Connect »

RUMC

Chicago, IL United States
  Connect »

Mayo

Rochester, MN United States
  Connect »

Holy Name Medical Center

Teaneck, NJ United States
  Connect »

UNC

Chapel Hill, NC United States
  Connect »

Summa Health

Akron, OH United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

Metro Health

Cleveland, OH United States
  Connect »

University Hospitals

Cleveland, OH United States
  Connect »

Lifespan Health System

Providence, RI United States
  Connect »

VCU

Richmond, VA United States
  Connect »

Medical College of Wisconsin

Milwauke, WI United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.